Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIT mixture of grass and mite allergens versus monotherapy or placebo in polysensitized allergic patients
2018-003715-22Phase 3Terminated
- Sponsor
- Inmunotek
- Start
- Nov 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of Beltavac and polymerized grass pollen allergenic extract in allergic asthma, allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and 2 more (4 arms), sponsored by Inmunotek. Started Nov 2020; status: terminated.
02
Drugs
Beltavacpolymerized grass pollen allergenic extract
03
Conditions
allergic asthmaallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergygrass pollen allergy
Beyond the preview
Go deeper on 2018-003715-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003715-22.